...
首页> 外文期刊>JMIR mHealth and uHealth >Clinical Feasibility of Monitoring Resting Heart Rate Using a Wearable Activity Tracker in Patients With Thyrotoxicosis: Prospective Longitudinal Observational Study
【24h】

Clinical Feasibility of Monitoring Resting Heart Rate Using a Wearable Activity Tracker in Patients With Thyrotoxicosis: Prospective Longitudinal Observational Study

机译:使用可穿戴活动追踪器监测甲状腺毒症患者静息心率的临床可行性:前瞻性纵向观察性研究

获取原文
           

摘要

Background Symptoms and signs of thyrotoxicosis are nonspecific and assessing its clinical status is difficult with conventional physical examinations and history taking. Increased heart rate (HR) is one of the easiest signs to quantify this, and current wearable devices can monitor HR. Objective We assessed the association between thyroid function and resting HR measured by a wearable activity tracker (WD-rHR) and evaluated the clinical feasibility of using this method in patients with thyrotoxicosis. Methods Thirty patients with thyrotoxicosis and 10 controls were included in the study. Participants were instructed to use the wearable activity tracker during the study period so that activity and HR data could be collected. The primary study outcomes were verification of changes in WD-rHR during thyrotoxicosis treatment and associations between WD-rHR and thyroid function. Linear and logistic model generalized estimating equation analyses were performed and the results were compared to conventionally obtained resting HR during clinic visits (on-site resting HR) and the Hyperthyroidism Symptom Scale. Results WD-rHR was higher in thyrotoxic patients than in the control groups and decreased in association with improvement of thyrotoxicosis. A one standard deviation–increase of WD-rHR of about 11 beats per minute (bpm) was associated with the increase of serum free T4 levels (beta=.492, 95% CI 0.367-0.616, P .001) and thyrotoxicosis risk (odds ratio [OR] 3.840, 95% CI 2.113-6.978, P .001). Although the Hyperthyroidism Symptom Scale showed similar results with WD-rHR, a 1 SD-increase of on-site rHR (about 16 beats per minute) showed a relatively lower beta and OR (beta=.396, 95% CI 0.204-0.588, P .001; OR 2.114, 95% CI 1.365-3.273, P .001) compared with WD-rHR. Conclusions Heart rate data measured by a wearable device showed reasonable predictability of thyroid function. This simple, easy-to-measure parameter is clinically feasible and has the potential to manage thyroid dysfunction.
机译:背景甲状腺毒症的症状和体征是非特异性的,通过常规体格检查和病史记录很难评估其临床状态。心率(HR)升高是对此进行量化的最简单标志之一,当前的可穿戴设备可以监视HR。目的我们评估了可穿戴活动追踪器(WD-rHR)测量的甲状腺功能与静息心率之间的关联,并评估了该方法在甲状腺毒症患者中的临床可行性。方法将30例甲状腺毒症患者和10例对照纳入研究。指示参与者在研究期间使用可穿戴活动跟踪器,以便可以收集活动和HR数据。主要研究结果是验证甲状腺毒症治疗期间WD-rHR的变化以及WD-rHR与甲状腺功能之间的关联。进行线性和逻辑模型广义估计方程分析,并将结果与​​临床就诊时常规获得的静息心率(现场静息心率)和甲亢症状量表进行比较。结果甲状腺毒性患者的WD-rHR高于对照组,并随着甲状腺毒性的改善而降低。 WD-rHR的一个标准偏差–大约每分钟11次搏动(bpm)的增加与血清游离T4水平的增加(β= .492,95%CI 0.367-0.616,P <.001)和甲状腺毒症的风险有关(赔率[OR] 3.840,95%CI 2.113-6.978,P <.001)。尽管甲亢症状量表显示与WD-rHR相似的结果,但现场rHR的1 SD升高(约每分钟16次搏动)显示相对较低的beta和OR(beta = .396,95%CI 0.204-0.588,与WD-rHR相比,P <.001; OR 2.114,95%CI 1.365-3.273,P <.001)。结论通过可穿戴设备测量的心率数据显示甲状腺功能的合理可预测性。这个简单易测量的参数在临床上是可行的,并且有可能治疗甲状腺功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号